# OnCo record paper-van-nimwegen-cardiovascular-disease-after-hodgkin-jama-intern-med-2015 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-van-nimwegen-cardiovascular-disease-after-hodgkin-jama-intern-med-2015/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-van-nimwegen-cardiovascular-disease-after-hodgkin-jama-intern-med-2015" ;
  schema:name "Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk"@en ;
  schema:alternateName "van Nimwegen 2015"@en, "Dutch Hodgkin cardiovascular cohort"@en ;
  schema:description "Half of 2,524 people treated for Hodgkin lymphoma developed heart or valve disease within forty years, and the risk was still four to six times the general population's after thirty-five years."@en ;
  schema:url <https://onco.cc/key-papers/paper-van-nimwegen-cardiovascular-disease-after-hodgkin-jama-intern-med-2015/> ;
  schema:dateModified "2026-10-01"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamainternmed.2015.1180>, <https://pubmed.ncbi.nlm.nih.gov/25915855/>, <https://europepmc.org/article/MED/25915855> ;
  onco:tag "lymphoma-evidence" ;
  schema:sameAs <https://doi.org/10.1001/jamainternmed.2015.1180> ;
  schema:datePublished "2015"^^xsd:gYear ;
  schema:author "van Nimwegen FA, Schaapveld M, Janus CP, et al." ;
  onco:related <https://onco.cc/key-papers/paper-schaapveld-second-cancer-risk-40-years-hodgkin-nejm-2015/>, <https://onco.cc/roadmaps/lymphoma-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/>, <https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/> ;
  onco:sections <https://onco.cc/fronts/radiation/>, <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/terms/radiotherapy/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/imrt-igrt/> ;
  onco:drugs <https://onco.cc/drugs/doxorubicin/> ;
  onco:trials <https://onco.cc/trials/hd10/>, <https://onco.cc/trials/hd16/>, <https://onco.cc/trials/radar-hodgkin/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-survivorship/>, <https://onco.cc/bottlenecks/b-toxicity-qol/>, <https://onco.cc/bottlenecks/b-aging-comorbidity/> ;
  onco:journals <https://onco.cc/journals/jama-internal-medicine/> .